Member Info for LochinvarLass

There's an interesting daft lassie question tagged onto the answer as to why CEPI can't give Inovio any funding, including Bermuda's Tweet of the preprint (which I believe Scancell retweeted)..

Just back in the glen and it is time to almost time to take the dog for a swim. Hope all are enjoying the splendid weather - thank goodness the kids are out of school to enjoy it.

Link: https://www.reuters.com/business/healthcare-pharmaceuticals/oxford-researchers-say-they-developed-blood-test-predictor-vaccine-efficacy-2021-06-24/

Researchers at Oxford University said on Thursday they have developed a method to predict the efficacy of new COVID-19 vaccines based on a blood test, potentially offering a short-cut around massive clinical trials that are increasingly difficult to conduct.

Anyone want to contact Scancell?

TF, thanks for posting this. I had been wondering whether there would be a. Large scale phase 3 trial if P1&2 probed the science.

By the time it comes to market, those initially protected may be losing their immunity, and Scancell could be on the perfect storm as we head into winter

For me Tuesdays news was stupendous. The fact that the market and the health journos don't get it yet just means that whatever spare cash u have can go into to buying more, albeit almost double my average cost.

My assumption is that any NED buy means that further news is a month out. I am not sure whether the 2+ company approach means that the parent is more or less of a takeover target, but I would have thought the 2 for 1 argument makes it a no trainer.

ATB C7 and and all contributors here.

Tagging some of the health journos in a tweet couldn't hurt - not that they have time to pick them all up :D

ATB all.

Agree GF. Hanging onto my hat just in case there is an acceleration.

Another gaslighting session - he doesn't have the qualifications to head any sort of science committee.

RR, I thought Thursdays were the day most Scancell RNSs appeared, which is why I said I thought it would be one of the last two Thursdays of June...

As you say, though, any day is a good day for the right RNS.

IDK, but I assume so as I paid 21.39 on Friday for a much smaller amount.

I don't understand why anyone would sell on the back of Friday's pre-print paper...

MiaV, agree with that.

ATB, LL

I am trying to read it over lunch, but it is hard going. Just about to check Twitter for any tweets.

I have just checked for my trade last week. The only reference to the price 21.39, is a 600 buy and I definitely bought more. (platform IG)

Quick question from someone who doesn't trade a lot. Do you think getting Level 2 pays off? Or should I just buy shares instead?

Added 1,900 at 21.39.

If I sell, I can almost guarantee that the price will shoot up to 360p.

Semiversary from the presentation, but the earliest dates Holloway gave were "H1", so they have a couple more weeks. He did say the cancer trials were dependent on the NHS having the bandwidth and permission to run them.

It would be great to see another shareholder presentation scheduled - even if their H1s have turned to Q3s and Q4s.

Good advice.

Weather is gorgeous here too - the pup had a swimming lesson in the sea this morning - just the thing to cool her off after chasing balls and frisbees. Walk number 3 today looms, right after a cuppa.

I am particularly interested in having shareholder value maximised..

ATB all. Back from a wet and windy walk on which the pup explored the waves crashing along the sea wall. She's sleeping contentedly now having had some dinner. Must be time for a wee dram somewhere.

Apologies for the double post - after a few minutes it looked like there was still no reply and I refreshed my screen several times. ATB

Don't think there is any need to ramp. Several said early on that the cash would be attractive. If the CTS are underway, having an experience sector M&A specialist on board will help ensure shareholder value is maximised.